OrbiMed Genesis GP LLC, Director, 10% Owner at ADARx Pharmaceuticals, Inc. (ADRX), bought 950,000 shares at $17.00 ($16.1M) on 2026-09-28, disclosed to the SEC on 2026-09-30.
OrbiMed Genesis GP LLC executed a $5.1 million purchase of 300,249 shares at $17.00, marking the largest insider transaction in the company's history and signaling strong conviction in the stock's post-IPO performance.
The stock is trading at $20.64, up 13.82% since its IPO on September 28, 2026, and is currently 10.65% below its 52-week high of $23.10.
1) Q3 earnings on November 4, 2026; 2) The company completed a US$446.25 million IPO on September 28, 2026, raising capital for its RNA-focused pipeline.
The stock is currently trading 13.82% above its IPO price of $17.00, indicating potential overvaluation risks immediately following the listing event.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $17.00 | 61,516 | $1.0M | 6.5% |
| 2 | $17.00 | 300,249 | $5.1M | 31.6% |
| 3 | $17.00 | 588,235 | $10.0M | 61.9% |
| Total | $17.00 avg | 950,000 | $16.1M | 100% |
| Filing → |
| KROS | SELL | 2024-08-15 | $11.0M | — | Filing → |
| TERN | SELL | 2024-07-17 | $562K | — | Filing → |
| IRON | BUY | 2024-06-20 | $3.0M | — | Filing → |